Company Acura Pharmaceuticals, Inc. Nasdaq
Equities
US00509L8028
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2020 | Weight | 2021 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
100.0
%
| 4 | 100.0 % | 2 | 100.0 % | -56.22% |
Sales per region
USD in Million | 2020 | Weight | 2021 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 4 | 100.0 % | 2 | 100.0 % | -56.22% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Robert Jones
CEO | Chief Executive Officer | 65 | 08-04-06 |
Peter Clemens
DFI | Director of Finance/CFO | 71 | 98-01-31 |
Bob Seiser
AUD | Comptroller/Controller/Auditor | 60 | 98-02-28 |
Albert Brzeczko
PRN | Corporate Officer/Principal | 67 | 09-01-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Clemens
DFI | Director of Finance/CFO | 71 | 98-01-31 |
Bruce Wesson
BRD | Director/Board Member | 81 | 98-02-28 |
William Skelly
BRD | Director/Board Member | 73 | 96-04-30 |
Director/Board Member | 53 | 02-11-30 | |
George Ross
BRD | Director/Board Member | 82 | 07-12-31 |
Robert Jones
CEO | Chief Executive Officer | 65 | 08-04-06 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 66,001,783 | 10,081,080 ( 15.27 %) | 0 | 15.27 % |
Company contact information
Acura Pharmaceuticals, Inc.
616 N. North Court Suite 120
60067, Palatine
+847 705 7709
http://www.acurapharm.comSector
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |